Next, we established the model of Golgi fragmentation using treatments with 5-FU and doxorubicin compounds and tracked the morphologic alterations in the organelle structure using antibodies against TGN38, a trans-Golgi network protein marker, followed by immunofluorescence and confocal microscopy assays in CRC cells. Here, TGOLN2 is linked to colorectal carcinoma.